T1	Participants 40 153	postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer
T2	Participants 169 194	Breast Cancer Study Group
T3	Participants 318 386	postmenopausal women with highly endocrine responsive breast cancer.
T4	Participants 457 575	12-93, postmenopausal women with node-positive, estrogen receptor (ER)-positive or ER-negative, operable breast cancer
T5	Participants 729 855	893 patients with endocrine-responsive disease, and according to prospectively defined categories of ER, age and nodal status.
T6	Participants 1281 1341	postmenopausal women with endocrine-responsive breast cancer
